Articles
-
Declaring the Vape Industry Illegal Will Only Drive It Underground
Declaring a multi-billion dollar industry illegal will only drive it underground. It will also make the health effects of vaping even more difficult to ascertain.
Categorized in -
Sharing Drug Rebates With Medicare Part D Patients: Why And How
The percentage of total Medicare Part D drug spending offset by rebates on branded drugs increased from 11% in 2010 to 25% in 2018.
Categorized in -
How Surprise Billing Increases Premiums—and How New Policies Could Help Consumers
A USC-Brookings Schaeffer Initiative for Health Policy research team finds that policies to limit surprise billing could also reduce insurance premiums for Americans by billions each year.
-
After Decades of Disappointment, a Turning Point Is Visible in Alzheimer’s Treatment
The USC-Brookings Schaeffer Initiative for Health Policy hosted a webinar featuring national thought leaders to examine hopeful signs in clinical development and policy that will ensure access to treatments and diagnostics.
Categorized in -
The COVID-19 Vaccine Model Needs to Prioritize ‘Superspreaders.’ Here is Why.
After taking care of essential workers, vaccinations should be given to the biggest transmitters of the virus – mostly the young – and only then to the most vulnerable.
Categorized in -
NIA-Funded Center Addresses Social, Economic Impacts of Alzheimer’s
The new center will explore innovative ways to ease the disease’s toll on individuals, families and caregivers while also developing strategies to reduce its burden on healthcare systems with an international team of researchers.
-
How To Boost Health Insurance Enrollment: Three Practical Steps That Merit Bipartisan Support
The authors explain how gaps in eligibility for federal assistance programs, perceptions of affordability, and administrative complexity create barriers that prevent millions of Americans from obtaining affordable coverage.
Categorized in -
Due to Complex Barriers, the Overwhelming Majority of Alzheimer’s Patients Do Not Participate in Clinical Trials
Improving clinical trial access and participation in Alzheimer’s disease trials could accelerate therapeutics to benefit the 1 in 10 Americans over age 65 who suffer from the condition.
Categorized in -
How to Ensure COVID-19 Doesn’t Delay Value-Based Care
The authors suggest supporting the adoption and existence of ACOs and preventing the loss of value-based opportunities via private equity or large hospital network acquisitions.
Categorized in -
Yes, We Need a Vaccine to Control COVID-19. But We Need New Treatments, Too.
New treatments for Covid-19 are needed before a vaccine is ready and as the essential backstop to manage it afterward, since vaccines aren’t perfect.
Categorized in